By John Lauerman
AstraZeneca Plc’s Lynparza got a boost from results of a study that may widen the drug’s use among patients with advanced ovarian cancer.
Ovarian tumor growth slowed in patients who got Lynparza in addition to a … Read more
By Amirah Al Idrus
PARP inhibitors have transformed treatment for breast and ovarian cancers, but their use has been limited to the small proportion of patients who have BRCA mutations. New research out of UT Southwestern Medical Center has uncovered … Read more
By Dave Levitan
An analysis of the phase III SOLO1 trial found no new safety signals when the PARP inhibitor olaparib was given as maintenance therapy for women with newly diagnosed advanced ovarian cancer and a BRCA mutation. Nausea, fatigue, … Read more
By Dave Levitan
Maintenance therapy with the PARP inhibitor rucaparib offered improved post-progression outcomes in a phase III trial of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who were in a complete or partial response to … Read more
Patients with BRCA-mutated, platinum-sensitive relapsed ovarian cancer derived significant clinical benefit from treatment with olaparib monotherapy compared with treatment of physician’s choice, according to the results of the SOLO3 trial, a US Food and Drug Administration … Read more
By Ian Ingram
Benefit seen across all subgroups for patients with platinum-sensitive disease.
Ovarian cancer patients with recurrent, platinum-sensitive disease experienced a longer interval without disease progression when bevacizumab (Avastin) was added to niraparib (Zejula), a phase II study found.… Read more
According to researchers at Yale Cancer Center, a cancer drug thought to be of limited use possesses a superpower of sorts: It is able to stop certain cancer cells from repairing their DNA in order to survive. The study, published … Read more
By Kristin Jenkins
The presence of a BRCA germ line mutation in patients with invasive epithelial ovarian cancer may confer a short-term survival advantage, but is not associated with a reduction in long-term mortality, researchers found.
A follow-up study comparing … Read more
By Dave Levitan
Niraparib showed promising and clinically relevant activity as therapy for heavily pretreated patients with ovarian cancer, according to a new phase II study. This was particularly true among women with homologous recombination deficiency (HRD)-positive tumors.
“Although most … Read more
By Christina Bennett, MS
Rucaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, was effective as a maintenance therapy across all age groups of patients with recurrent ovarian cancer, according to the results of a post-hoc exploratory analysis of ARIEL3 presented at … Read more
By Kristie L. Kahl
Side effects decreased among patients with high-risk ovarian cancer who received an individualized starting dose of Zejula (niraparib), based upon baseline bodyweight and platelet counts, compared with a fixed starting dose, according to a recent analysis
… Read moreBy Ian Ingram
Study identifies subgroup for whom another go could be worthwhile.
Lack of response to a PARP inhibitor in epithelial ovarian cancer didn’t necessarily mean patients were resistant to all such agents, a small retrospective study indicated.
Among … Read more
By Ian Ingram
In delaying disease progression in recurrent ovarian cancer, maintenance therapy with the PARP inhibitor niraparib (Zejula) also increased patients’ time without symptoms or toxicity (TWiST), an analysis of the phase III NOVA trial found.
Compared with placebo, … Read more
Since tumors often have unique defects in the DNA damage response (DDR) pathway, identifying the molecular mechanisms that underlie how cells repair various DNA lesions is critical to selecting the appropriate clinical treatments. Inhibitors to poly-(ADP-ribose) polymerase (PARP) are examples … Read more
By Brielle Benyon
The Food and Drug Administration (FDA) approved Lynparza (olaparib) for the maintenance treatment of adults with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in a
… Read moreReal-world experience of adverse events with the oral PARP inhibitor niraparib in patients with platinum-sensitive recurrent ovarian cancer at a 200 mg daily dose differed from those most commonly seen in the phase 3 clinical trial at … Read more
By
A new ovarian cancer treatment dramatically reduces the chances of the disease returning, a study has shown.
Doctors have hailed the results of a “breakthrough” trial which they say opens the possibility that many more women suffering … Read more
The extent to which the BRCA1 promoter is methylated could signal an ovarian tumor’s susceptibility to PARP inhibitor treatment, a new study has found.
PARP inhibitor treatment has been effective in treating some patients with high-grade serous ovarian carcinoma with … Read more
Cancer is never an easy foe, but some types are more stubborn than others. Ovarian cancer is one of the hardest to treat.
But there are signs of progress. Several recent studies have used new combination treatment strategies, including a … Read more
